Abstract |
Numerous solid tumors overexpress or have excessively activated insulin-like growth factor receptor-1 (IGF-1R). We summarize preclinical studies and the first-in-human study of KW-2450, an oral tyrosine kinase inhibitor with IGF-1R and insulin receptor (IR) inhibitory activity. Preclinical activity of KW-2450 was evaluated in various in vitro and in vivo models. It was then evaluated in a phase I clinical trial in 13 patients with advanced solid tumors (NCT00921336). In vitro, KW-2450 inhibited human IGF-1R and IR kinases (IC50 7.39 and 5.64 nmol/L, respectively) and the growth of various human malignant cell lines. KW-2450 40 mg/kg showed modest growth inhibitory activity and inhibited IGF-1-induced signal transduction in the murine HT-29/GFP colon carcinoma xenograft model. The maximum tolerated dose of KW-2450 was 37.5 mg once daily continuously; dose-limiting toxicity occurred in two of six patients at 50 mg/day (both grade 3 hyperglycemia) and in one of seven patients at 37.5 mg/day (grade 3 rash). Four of 10 evaluable patients showed stable disease. Single-agent KW-2450 was associated with modest antitumor activity in heavily pretreated patients with solid tumors and is being further investigated in combination therapy with lapatinib/ letrozole in patients with human epidermal growth factor receptor 2-postive metastatic breast cancer.
|
Authors | Gary K Schwartz, Mark A Dickson, Patricia M LoRusso, Edward A Sausville, Yoshimi Maekawa, Yasuo Watanabe, Naomi Kashima, Daisuke Nakashima, Shiro Akinaga |
Journal | Cancer science
(Cancer Sci)
Vol. 107
Issue 4
Pg. 499-506
(Apr 2016)
ISSN: 1349-7006 [Electronic] England |
PMID | 26850678
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
Chemical References |
- Protein Kinase Inhibitors
- ERBB2 protein, human
- Receptor, ErbB-2
- Receptor, IGF Type 1
- Receptor, Insulin
|
Topics |
- Adult
- Aged
- Animals
- Breast Neoplasms
(drug therapy, genetics, pathology)
- Cell Line, Tumor
- Colonic Neoplasms
(drug therapy, genetics, pathology)
- Female
- Humans
- Maximum Tolerated Dose
- Mice
- Protein Kinase Inhibitors
(administration & dosage)
- Receptor, ErbB-2
(genetics)
- Receptor, IGF Type 1
(biosynthesis, genetics)
- Receptor, Insulin
(biosynthesis, genetics)
- Signal Transduction
(drug effects)
- Xenograft Model Antitumor Assays
|